Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer

Ajaz Bulbul, Patrick M. Forde, Ayesha Murtuza, Brian Woodward, Hannah Yang, Ingmar Bastian, Parissa K. Ferguson, Fernando Lopez-Diaz, David S. Ettinger, Hatim Husain

Research output: Contribution to journalReview article

Abstract

Brain metastases are common in patients with non-small-cell lung cancer (NSCLC). Because of associated poor prognosis and limited specific treatment options, there is a real need for the development of medical therapies and strategies for affected patients. Novel compounds for epidermal growth factor receptor-dependent and anaplastic lymphoma kinase-dependent lung cancer have demonstrated blood-brain barrier permeability and have led to important improvements in central nervous system outcomes. Studies of targeted therapies for oncogene-driven tumors and of immunotherapies in patients with brain metastases have shown promise and, allied with novel radiation techniques, are driving a rapid evolution in treatment and prognosis for NSCLC brain metastases.

Original languageEnglish (US)
Pages (from-to)156-163
Number of pages8
JournalOncology (Williston Park, N.Y.)
Volume32
Issue number4
StatePublished - Apr 15 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this

    Bulbul, A., Forde, P. M., Murtuza, A., Woodward, B., Yang, H., Bastian, I., Ferguson, P. K., Lopez-Diaz, F., Ettinger, D. S., & Husain, H. (2018). Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer. Oncology (Williston Park, N.Y.), 32(4), 156-163.